Adalimumab Therapeutic Drug Monitoring Improves Treatment Outcome in Patients with Psoriasis

Therapeutic drug monitoring (TDM) or the measurement of drug concentrations (ideally at trough level) and antidrug antibodies are important tools for optimizing biologic therapy. Limited studies evaluated TDM in dermatological indications. A retrospective study of 170 patients with psoriasis who wer...

Full description

Saved in:
Bibliographic Details
Published inJournal of investigative dermatology Vol. 143; no. 9; pp. 1625 - 1628
Main Authors Alavi, Afsaneh, Loftus, Edward V.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2023
Online AccessGet full text
ISSN0022-202X
1523-1747
1523-1747
DOI10.1016/j.jid.2023.03.1676

Cover

More Information
Summary:Therapeutic drug monitoring (TDM) or the measurement of drug concentrations (ideally at trough level) and antidrug antibodies are important tools for optimizing biologic therapy. Limited studies evaluated TDM in dermatological indications. A retrospective study of 170 patients with psoriasis who were treated with adalimumab and received TDM reported that adalimumab TDM is practical and promising in routine psoriasis care. However, TDM interpretation requires careful attention to the clinical context to address the controversies and challenges.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:0022-202X
1523-1747
1523-1747
DOI:10.1016/j.jid.2023.03.1676